#976 2001 · Cipla (Yusuf Hamied) · Pharmaceuticals
Cipla combined three patented AIDS drugs into one generic pill, cutting price 97 percent
the problem
Patented triple-therapy HIV treatment cost over $12,000 a year, out of reach for Africa's millions infected
background
By 2000, effective HIV treatment existed — a triple combination of antiretroviral drugs that could turn AIDS from a death sentence into a manageable condition — but each of the three drugs was patented separately by a different multinational, and together they cost well over $12,000 per patient per year. Across Africa, where the epidemic was killing millions and annual health budgets per person ran to a few dollars, that price was not a hardship, it was a wall: fewer than one in a thousand who needed the drugs could get them. International patent law, and the diplomatic weight of the companies that held it, made the price look immovable.
Global health agencies pushed for donated doses and charitable discounts, but donations depended on the patent holders' goodwill and covered a sliver of the need, while lobbying for compulsory licensing meant years of legal and diplomatic fights against the world's largest drug companies. Yusuf Hamied, chairman of the Indian generics maker Cipla, was sitting on a legal opening the multinationals didn't have: India's 1970 Patents Act, which Hamied himself had lobbied for decades earlier, recognized patents on drug processes but not on the drugs themselves — so an Indian manufacturer could legally produce the same molecule made a different way.
what everyone would do
Lobby the patent holders for donated doses or steep discounts, or push governments to invoke compulsory licensing through years of legal battle against companies with far larger legal budgets — both routes that leave the price, and the timeline for lowering it, in the multinationals' hands.
what they saw
Hamied saw the patents blocking cheap AIDS drugs elsewhere didn't apply in India, which protected a drug's process, not the drug itself. He didn't need permission — just to build it and price it low.
the move
Cipla's chemists reverse-engineered manufacturing routes for the three drugs, combined them into a single fixed-dose pill, and in 2001 offered the finished triple-therapy to Médecins Sans Frontières for $350 a year per patient — later cut further to under a dollar a day — without infringing an Indian patent.
why it works
The move works because it doesn't ask incumbents to lower their price — it makes their price irrelevant by supplying a legal substitute nobody can block. Once Cipla's $1-a-day offer existed publicly, patent holders faced a choice between matching it or watching their market defect to a generic they had no legal way to stop, so the price cut became self-enforcing rather than something Cipla had to fight for country by country.
the payoff
The offer collapsed rivals' prices within months; by the mid-2000s millions across the developing world were on generics modeled on it.
where it breaks
It only works where the legal gap exists — countries that recognize product patents on drugs themselves close this route entirely, which is why India tightened its own patent law in 2005 under WTO pressure. It also requires the generic maker to have the manufacturing sophistication to replicate a patented molecule through a different process, and it invites the litigation and trade pressure patent holders can bring in every market where the loophole doesn't exist.
what came after
Cipla's move is credited with breaking Big Pharma's pricing monopoly on AIDS treatment and helped establish the generic fixed-dose-combination model that still supplies most HIV treatment in the developing world today.
references
- [1]CIPLA: Taking On Big PharmaLive History India, 2022livehistoryindia.com